secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001438533-24-000038
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere pauses Phase 3 HCU trial enrollment due to manufacturing scale-up issues; restart expected in 2026
--------------------------------------------------------------------------------

- Voluntary pause of enrollment in Phase 3 HARMONY Study for pegtibatinase (classical homocystinuria).
- Desired drug substance profile not achieved in recent scale-up process; process improvements needed.
- Currently enrolled patients continue to receive study medication from small scale batches without disruption.
- Earliest date to restart enrollment expected in 2026 while company evaluates commercial process improvements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000038/0001438533-24-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000038/tvtx-20240926.htm
  HTML page:      https://secwatch.observer/filing/0001438533-24-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer